763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797384417374633984 |
|---|---|
| author | Ning Li William L Redmond Brendan Curti Shuhang Wang Herui Yao Erwei Song Henry Yu Giorgio Massimini Ming-Hong Hu Rongliang Lou Wanping Geng Sanlong Wang Meiling Zhang Rongchu Chen Baotian Qin John Mao Shaoshan Wang |
| author_facet | Ning Li William L Redmond Brendan Curti Shuhang Wang Herui Yao Erwei Song Henry Yu Giorgio Massimini Ming-Hong Hu Rongliang Lou Wanping Geng Sanlong Wang Meiling Zhang Rongchu Chen Baotian Qin John Mao Shaoshan Wang |
| author_sort | Ning Li |
| collection | DOAJ |
| first_indexed | 2024-03-08T21:35:17Z |
| format | Article |
| id | doaj.art-7b531028babd4a6d95e0a4b089285ad9 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-08T21:35:17Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-7b531028babd4a6d95e0a4b089285ad92023-12-20T23:05:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0763763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignanciesNing Li0William L Redmond1Brendan Curti2Shuhang Wang3Herui Yao4Erwei Song5Henry Yu6Giorgio Massimini7Ming-Hong Hu8Rongliang Lou9Wanping Geng10Sanlong Wang11Meiling Zhang12Rongchu Chen13Baotian Qin14John Mao15Shaoshan Wang163Chinese Academy of Medical Sciences, Beijing, China7Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA5Providence Cancer Institute, Franz Clinic, Portland, OR, USA4Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China2Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China11Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China1CanWell Pharma Inc, Woburn, MA, USA1CanWell Pharma Inc, Woburn, MA, USA6CanWell Pharma Inc., Woburn, MA, USA1CanWell Pharma Inc, Woburn, MA, USA8CanWell Pharma, Woburn, MA, USA1CanWell Pharma Inc, Woburn, MA, USA1CanWell Pharma Inc, Woburn, MA, USA1CanWell Pharma Inc, Woburn, MA, USA1CanWell Pharma Inc, Woburn, MA, USA9JWM Pharma, San Francisco, CA, USA10Canwell Pharma Inc, Newton, MA, USA |
| spellingShingle | Ning Li William L Redmond Brendan Curti Shuhang Wang Herui Yao Erwei Song Henry Yu Giorgio Massimini Ming-Hong Hu Rongliang Lou Wanping Geng Sanlong Wang Meiling Zhang Rongchu Chen Baotian Qin John Mao Shaoshan Wang 763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies Journal for ImmunoTherapy of Cancer |
| title | 763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies |
| title_full | 763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies |
| title_fullStr | 763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies |
| title_full_unstemmed | 763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies |
| title_short | 763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies |
| title_sort | 763 initial results from phase i dose escalation trial of can1012 in patients with solid tumor malignancies |
| work_keys_str_mv | AT ningli 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT williamlredmond 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT brendancurti 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT shuhangwang 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT heruiyao 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT erweisong 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT henryyu 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT giorgiomassimini 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT minghonghu 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT ronglianglou 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT wanpinggeng 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT sanlongwang 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT meilingzhang 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT rongchuchen 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT baotianqin 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT johnmao 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies AT shaoshanwang 763initialresultsfromphaseidoseescalationtrialofcan1012inpatientswithsolidtumormalignancies |